Beta-carbolin H1-receptor antagonists

Details Beta-carbolin H1-receptor antagonists Beta-carbolin H1-receptor antagonists

1987-02-26

1988-08-23

Daus, Donald G.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

544362, A61K 31495, C07D40314

Patent

active

047661240

ABSTRACT:
The method of using compounds of the formula: ##STR1## in which R.sup.1 is hydrogen or 4-halophenyl; R.sup.2 is 4-halophenyl when R.sup.1 is 4-halophenyl and 3-trifluoromethylphenyl and R.sup.1 is hydrogen; and n is one of the integers 2, 3 or 4; or a pharmaceutically acceptable salt thereof as histamine H.sub.1 -receptor antagonists and the novel compound 2,3,4,9-tetrahydro-2-[3-[4-[3-(trifluoromethyl)benzyl]-1-piperazinyl]propy l]-1H-pyridol[3,4-b]indole represent the inventive aspects of this disclosure.

REFERENCES:
patent: 4575508 (1986-03-01), Steiner et al.
patent: 4663456 (1987-05-01), Abou-Gharbia
Derwent Abstract 20,387 (Jap. 2713/66; 2/21/66).

Affiliated with

Also associated with

Rating

Beta-carbolin H1-receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Beta-carbolin H1-receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Beta-carbolin H1-receptor antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-836035